trial

A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

NCTId NCT01979679
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 28 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2013-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
28 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-12
Primary completion
2013-10
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
Dainippon Sumitomo Pharma AmericaCollaborator

Investigators

1
Steven G Potkin, MDPrincipal Investigator

Sites

1 total
Orange, United States

Linked catalysts

1
A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lu — primary completion2013-10

Facts & assertions

4 sourced
Enrollment
28
Phase
PHASE3
Primary Completion Date
2013-10
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
Dainippon Sumitomo Pharma America
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Steven G Potkin, MD
person